[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638264":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":39,"centralContacts":43,"locations":49,"responsibleParty":69,"collaborators":72,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":31,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":31,"enrollmentInfo":85,"targetDuration":31,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":31,"overallStatus":51,"whyStopped":31,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Ohio State University Comprehensive Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Supportive care (I-CAN)","EXPERIMENTAL","Patients participate in online I-CAN training sessions over approximately 2.5 hours per week for 4 weeks before and 4 weeks after CAR-T therapy for a total of 20 hours over 8 weeks. Patients also undergo collection of blood samples throughout the study.",[13,14,15,16],"Procedure: Biospecimen Collection","Other: Cognitive Intervention","Other: Electronic Health Record Review","Other: Survey Administration",[18,27,32,36],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"PROCEDURE","Biospecimen Collection","Undergo collection of blood samples",[9],[24,25,26],"Biological Sample Collection","Biospecimen Collected","Specimen Collection",{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Cognitive Intervention","Participate in I-CAN training sessions",[9],null,{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Electronic Health Record Review","Ancillary studies",[9],{"type":6,"name":37,"description":34,"armGroupLabels":38,"otherNames":31},"Survey Administration",[9],[40],{"name":41,"affiliation":5,"role":42},"Ashley E Rosko, MD","PRINCIPAL_INVESTIGATOR",[44],{"name":45,"role":46,"phone":47,"phoneExt":31,"email":48},"The Ohio State University Comprehensive Cancer Center","CONTACT","800-293-5066","OSUCCCClinicaltrials@osumc.edu",[50],{"facility":5,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"RECRUITING","Columbus","Ohio","43210","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-82.99879,39.96118,{"lat":61,"lon":60},[64,68],{"name":65,"role":46,"phone":66,"phoneExt":31,"email":67},"Ashley E. Rosko, MD","614-688-7397","Ashley.Rosko@osumc.edu",{"name":65,"role":42,"phone":31,"phoneExt":31,"email":31},{"type":42,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Ashley Rosko","Principal Investigator",[73],{"name":74,"class":75},"National Institutes of Health (NIH)","NIH","100638264","a-cognitive-training-intervention-for-improving-cognitive-and-neurological-outcomes-in-patients-undergoing-treatment-for-relapsed-or-refractory-multiple-myeloma-or-b-cell-non-hodgkin-lymphoma-100638264",false,"NCT07609030","A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma","Intervention to Enhance Cognitive Augmentation and Neuroplasticity (I-CAN)","Inclusion Criteria:\n\n* Patients \\>= 18 years of age\n* Diagnosed with relapsed\u002Frefractory multiple myeloma (MM) or B-cell non-Hodgkin lymphoma (B-NHL)\n* Expected to receive an Food and Drug administration (FDA)-approved CAR-T cellular treatment\n* English literacy\n\nExclusion Criteria:\n\n* Patients expected to live \\\u003C 6 months\n* Patients with major medical disorder known to affect cognition, such as stroke, encephalitis, traumatic brain injury, brain surgery\n* Confirmed Alzheimer disease or other dementia\n* Previous central nervous system (CNS) radiation\n* Active intrathecal therapy at time of enrollment","ALL","18 Years",{"count":86,"type":87},90,"ESTIMATED","INTERVENTIONAL",[90],"NA","This clinical trial evaluates whether an online cognitive training intervention (Intervention to enhance Cognitive Augmentation and Neuroplasticity \\[I-CAN\\]), delivered before and after treatment with chimeric antigen receptor T-cell therapy, works to improve cognitive and neurological outcomes in patients with multiple myeloma or B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Cancer treatment can have significant short and long-term side effects, including cognitive and neurological side effects such as impairments in attention, memory, language, and executive function. The I-CAN program is a form of cognitive training. Cognitive training is a therapeutic approach designed to improve and restore cognitive functioning, based on the brain's ability to reorganize and form new neural connections to accomplish tasks. I-CAN provides five core elements necessary for training the brain to create new neural connections including speed of processing, accuracy of processing, adaptivity, generalizability, and engagement. The I-CAN intervention, when delivered before and after therapy, may help reduce the cognitive side effects of treatment in patients with relapsed or refractory multiple myeloma or B-cell non-Hodgkin lymphoma.",[93,94,95,96],"Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Multiple Myeloma","Refractory B-Cell Non-Hodgkin Lymphoma","Refractory Multiple Myeloma","2026-05-19",{"date":99,"type":100},"2026-05-27","ACTUAL",{"date":102,"type":100},"2026-04-28",{"date":104,"type":87},"2027-12-31",{"name":5,"class":6},1]